PDCD1 and neoplasm: Anti-PD1 and anti-PD-L1/2 therapeutic antibodies can interfere with the interactions between PD1 and its ligands, resulting in the enhancement of anti-tumor immunological response caused by cytotoxic T cells [10,11].